Form 4 for AKBA Akebia Therapeutics, Inc.
Accepted 2023-02-02 00:00:00 ET · period of report 2023-01-31 · accession 0001562180-23-000832 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-02 | 2023-01-31 | AKBA | Butler John P. | CEO, Pres, Dir | A - Grant | $0.00 | +293.1K | 1.70M | +21% | $0 |
| DM | 2023-02-02 | 2023-01-31 | AKBA | Butler John P. | CEO, Pres, Dir | A - Grant | $0.00 | +1.51M | 635.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-31 | A | A | 293,125 | $0.00 | 1,699,372 | D | — | — | (F1) The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. (F2) Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2022 and 1,500 shares of the Issuer's common stock purchased on December 30, 2022, each under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan. |
| 2 | Derivative | Stock Option (Right to buy) | 2023-01-31 | A | A | 875,000 | $0.00 | 875,000 | D | $0.63 · — to 2033-01-31 | 875,000 Common Stock | (F4) The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. |
| 3 | Derivative | Stock Appreciation Right | 2023-01-31 | A | A | 635,313 | $0.00 | 635,313 | D | $0.63 · — to 2033-01-31 | 635,313 Common Stock | (F3) The stock appreciation rights ("SARs") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The SARs will vest over four years: 25% of the SARs will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. |